Infection of respiratory cultures treated with the Janus kinase (JAK) inhibitor Ruxolitinib (Ruxo; 5 μM), which blocks IFN-mediated JAK–STAT signaling during virus infection [40,41], demonstrated no significant change in SARS-CoV-2 apical titers relative to carrier control (DMSO) treatment (Fig 6G). The gene discussed is IFNA1; the disease is viral infectious disease.